IPP Bureau
Lupin signs exclusive licensing pact with Neopharmed for Plasil in Philippines and Brazil
By IPP Bureau - December 19, 2025
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Gilead’s new HIV therapy shows promising Phase 3 results
By IPP Bureau - December 19, 2025
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
By IPP Bureau - December 19, 2025
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe
By IPP Bureau - December 19, 2025
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Roche unveils major upgrade to cobas 6800/8800 systems, boosting lab efficiency
By IPP Bureau - December 19, 2025
The update promises to revolutionize laboratory workflows by optimizing resources
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
By IPP Bureau - December 19, 2025
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
SABIC launches first fluorine-free polycarbonate resin to boost medical device safety
By IPP Bureau - December 19, 2025
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
ystral expands in India with new Bangalore facility, boosting team & local production
By IPP Bureau - December 19, 2025
The expansion includes a larger technical and service team and increased local procurement
Novo Nordisk files FDA application for once-weekly obesity drug CagriSema
By IPP Bureau - December 19, 2025
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
JHS Svendgaard to invest Rs. 25 crore on building new manufacturing unit
By IPP Bureau - December 19, 2025
The new facility is expected to generate 500-600 new jobs in the region
Max Healthcare announces Rs.1,000-cr foray into Pune with 450-bed super speciality hospital
By IPP Bureau - December 19, 2025
The state-of-the-art facility is expected to be commissioned over the next three years
Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron
By IPP Bureau - December 19, 2025
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
GenSci, RTW & Yarrow Bioscience strike $1.365 billion global deal for breakthrough graves’ disease therapy
By IPP Bureau - December 19, 2025
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Agilent Technologies opens India Refurbishment Center
By IPP Bureau - December 19, 2025
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
,_Thyrocare.jpg "Thyrocare appoints Dr Ramesh Kinha as COO")
Thyrocare appoints Dr Ramesh Kinha as COO
By IPP Bureau - December 19, 2025
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
